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Abbreviated Title Page 
1. Manuscript title: 
 Size-tuneable nanometric MRI contrast agents for the imaging of molecular weight 
dependent transport processes 
2. Manuscript type:  
Original research 
3. Advance(s) in Knowledge (5 sentences): 
1. Precise control of glycol chitosan (GC) polymer chemistry facilitates synthesis of 
Gadolinium based MRI contrast agents with identical physicochemical properties but 
defined molecular weight  
2. GC-DTAP-Gd provides enhanced contrast over an extended duration depending on 
molecular weight MW (≥ 1h for 40kD).   
3. Kidneys show early detailed enhancement of medulla, papilla and renal pelvis suggesting 
renal elimination.  
4. Imaging of the head with GC-DTPA-Gd allowed detailed anatomical identification of 
specific blood vessels in particular with the high MW agent.  
5. Sequential high-resolution isotropic imaging of established A431 xenograft flank 
tumours with DTPA-Gd and GC-DTPA-Gd demonstrated that the initial delivery of 
the contrast agents was well correlated with blood supply but subsequent tissue 
transport was heterogeneous and primarily by diffusion, limited by molecular weight.  
4. Implication(s) for Patient Care (if any) 
 MRI imaging of molecular weight dependent transport processes which could potentially 
lead to clinical biomarkers for molecular weight dependent drug transport and support 
selection of suitable tumour models for pre-clinical development. 
5. One sentence summary statement 
Precise control of glycol chitosan polymer chemistry facilitates synthesis of Gd based MRI 
contrast agents with defined molecular weights which allow isotropic high-resolution three-
dimensional imaging of molecular weight dependent transport processes that could serve as 
predictive biomarkers for drug transport. 
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6. Abstract (250) 
Purpose: To evaluate size-tuneable nanomeric glycol-chitosan-DTPA-Gd conjugates as MRI contrast 
agents for the imaging of molecular weight (MW) dependent transport processes. 
 
Material & Methods: Glycol chitosans (GC) – DTPA conjugates of precisely controlled MWs were 
synthesised and evaluated in mice against Gd-DTPA using times series of high-resolution MRI 
images of trunk, head, and xenograft flank tumours. All animal studies were approved by the local 
ethics committee and the UK authorities.  
 
Results:  GC-DTPA modification ratio was one DTPA per 3.9 – 5.13 of GC monomers. GC-DTAP-
Gd provided overall superior contrast compared to Gd-DTPA with the duration of the 
enhancement depending on MW (≥ 1h for 40kD).  Kidneys showed early enhancement also in the 
renal pelvis suggesting renal elimination. Imaging of the head with GC-DTPA-Gd allowed detailed 
anatomical identification of specific blood vessels in particular with the high MW agent. Sequential 
high-resolution isotropic imaging of established A431 xenograft flank tumours with DTPA-Gd and 
GC-DTPA-Gd demonstrated that the initial delivery of the contrast agents was well correlated with 
blood supply. Subsequent tissue transport was primarily by diffusion and was limited by molecular 
weight. The data also highlight the role of heterogeneity in CA distribution that was again more 
prominent for the high MW agent. 
 
Conclusion: GC-DTPA-Gd with identical physical chemical properties but precisely controlled MW 
allow isotropic high-resolution three-dimensional imaging of molecular weight dependent transport 
processes which could potentially lead to clinical biomarkers for molecular weight dependent drug 
transport and support selection of suitable tumour models for pre-clinical development. 
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7. Introduction (400/394) 
Around 50% of MRI studies use contrast agents (CA) such as Gadolinium (Gd) [1] which is typically 
administered in a chelated form to avoid the toxicity from free Gd. Most CAs in current clinical use 
are extracellular fluid agents that distribute readily to all tissues and are typically excreted rapidly by 
renal filtration due to their low molecular weight (MW)[2]. However, CAs that remain limited to 
the blood vessels and have an extended plasma half-life are also useful, e.g. for imaging studies of 
longer duration and imaging of the blood vessels in MR angiography. Such blood pool CAs would 
typically require molecular weights large enough to avoid extravasation and ready renal filtration, 
e.g. by binding of Gd-chelates to albumin (MW69kD, 7-8 nm) [3, 4]. Gadofosveset trisodium 
(Ablavar®, Bayer Schering Pharma AG) is the first FDA licensed blood pool CA on the market [5]. 
Blood pool agents provide potential advantages for the visualisation of peripheral vascular 
pathology, vascular aspects of CNS or kidney disease, and cancer. For example, the progression of 
solid tumours requires the obligatory activation of the ‘angiogenic switch’, i.e. the activation of 
pathways linked to the development of new blood vessels[6]. The developing neo-vasculature is 
heterogeneous with atypical morphology, and has reduced hydrodynamic and transport 
functionality. The discontinuous endothelial lining allows extravasation of macromolecules and nano-
sized particulates[7] with a consequent increase in interstitial pressure that hampers nutrient and 
drug transport into the tumour parenchyma [8] and has been linked to poor prognosis and drug 
resistance [9]. The effects are thought to be particularly important for the transport of higher MW 
therapeutics such as anti-bodies, macromolecules, particulate drug carriers, and gene delivery 
systems [10]. Understanding the impact of MW on transport processes from blood vessels into 
tissues thus becomes important not only as a diagnostic feature but also as a potential predictor 
and biomarker for transport of such agents in specific tumours. 
We hypothesised that polymeric MRI CAs of variable MW but identical physicochemical properties 
could be a useful tool for the study of such molecular weight dependent transvascular transport 
processes and chose to test this by creating CAs based on glycol chitosan (GC), a versatile 
biocompatible carbohydrate polymer widely used in the development of nanomedicines and nano-
diagnostics. 
8. Materials and Methods (800/788) 
8.1. Synthesis of GC-DTPA 
All reagents were purchased from Sigma-Aldrich, UK. Glycol chitosan (GC) of varying molecular 
weight was obtained by acid degradation [11]. Briefly, GC with a degree of polymerisation of 2,500 
was degraded (2 h, 48 h) and recovered by filtration, dialysis, and freeze-drying. The depolymerised 
GC was then reacted with p-SCN-Bn-DTPA (2-(4-isothiocyanatobenzyl)-diethylenetriamine 
pentaacetic acid, Macrocyclics, USA)in alkaline conditions (24h) and the product obtained after 
dialysis and freeze-drying. The polymer MW was determined by gel permeation chromatography 
and multi-angle laser light scattering (GPC/MALLS; Dawn EOS, Wyatt Technology) [11]. 1H-NMR 
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and 1H-1H COSY (Bruker AMX 400 MHZ spectrometer) were performed on GC, p-SCN-Bn-
DTPA, and GC-DTPA conjugates using deuterated water (D2O). Elemental analysis was carried out 
on a Thermo Finnigan EA1112 instrument (Thermo Scientific). 
8.2. Gadolinium Loading  
GC-DTPA conjugate and gadolinium (0.5 mmol) were dissolved in imidazole buffer (pH=6.8), 
mixed and stirred over night to form a precipitate (GC-DTPA-Gd) which was re-dissolved at pH7 
to precipitate free Gd. After Gd removal by filtration (0.45µm) and dialysis the final product was 
obtained by freeze-drying. The Gd loading of the GC-DTPA polymer was confirmed using 
isothermal titration calorimetry (ITC), the arsenazo assay, and inductively coupled plasma–atomic 
emission (ICP-AE): For the ITC (Microcal VP-ITC, MicroCal Inc., USA) Gd chloride hexahydrate 
(6.5mM), DTPA and GC-DTPA (0.2mM DTPA equivalent) were dissolved (0.1M HCl/NaOH 
buffer, pH = 2) and de-gassed (ThermoVac, MicroCal Inc., USA).Then aliquots of Gd (20–25 x 5µL, 
Δt 6 mins) were injected into the ITC cell filled with either DTPA or GC-DTPA (n=3). Free Gd in 
solutions of DTPA or GC-DTPA was quantified using the absorbance of a Gd-arsenazo complex 
(653 nm) [12]. The Gd content in a range of samples of GC-DTPA-GD was measured using ICP-
AE (138 UL Trace, Jobin Yvon, UK; Vista Pro, Varian Inc.) and Gd standards (0-40 mg L-1) at 310 
nm. 
8.2.1. Animal Preparation and Maintenance 
All studies adhered to current national and local regulations and guidelines [13]. Female nude mice 
(CD1-nu, ~20 g)were anaesthetized (2–3% isofluorane in 70/30 N2/O2) via a facemask. 
Temperature (water jacket), respiration and ECG were monitored using a BIOPAC system (Goleta, 
CA, U.S.A.). Xenograft tumours, established by subcutaneous injection of 1x106A431 epidermoid 
carcinoma cells (ATCC CRL-1555), were used when vascularized (⌀> 5 mm 10+ days). 
8.3. MR Imaging 
All MR imaging was performed on a Bruker Biospin Advance using a 7T horizontal 30cm bore 
magnet. Trunk imaging was carried out with a 35mm RF resonator coil (gradient maximum 200mT 
m-1), other images used a Bruker micro-imaging gradient insert (BG-6, 60mm ID, 100A amplifier; 
gradient maximum 1000 mTm-1, rise time of 50 µs) or a dedicated optimized tumour solenoid RF 
micro-coil, built into the animal cradle [14]. 
The trunk with a focus on the kidneys was imaged using a four slice multi slice multi echo (MSME) 
2D sequence with in-plane isotropic voxels 150 × 150 µm2, slice thickness of 2 mm, in-plane FoV 
60 × 34 mm. The sequence (TE=10.5 ms, TR=75 ms, a flip angle of 90° with a 180° re-focusing 
pulse and four averages) required a total scan time of 1 minute 7 seconds. 
 
The brain was imaged using a 3D FLASH sequence with isotropic voxels 160 × 160 × 160 µm3 and 
a field of view 20 × 16 × 16 mm3. This sequence used an echo time of 3.7 ms, a repetition time of 
20 ms, a flip angle of 30°, and one average. The total scan time was 3 minutes 20 seconds. 
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A 3D FLASH sequence was also used to image tumours using isotropic 100 µm3 voxels in a field of 
view 80 mm3 with an echo time of 3.5 ms, a repetition time of 25.0 ms, a flip angle of 30°, and 
either two or four averages with total scan times of 5 min 20 sec and 10 min 40 sec, respectively. 
Tumour angiography studies used a multi-slice 2D time of flight (TOF) gradient echo sequence 
sliced perpendicular to the axis of the coil or sagittal in anatomical terms with isotropic 100 µm3 
voxels in-plane resolution and 60 sequential slices of 100 µm thickness. The echo time used was 5 
ms and the recovery time was 40 ms with 8 averages. 
Raw data was exported as free induction decay (FID) file and then processed using Interactive Data 
Language (IDL, RSI, Boulder, Colorado, U.S.A.) routines. 
 
9. Results (1000/1062) 
9.1. GC-DTPA Synthesis 
The acid degradation of glycol chitosan reduces the polymer MW in a nonlinear manner following a 
first order reaction with a first order rate constant of −1.346 (Mn = 94448 e−1.346t + 7041, r2 = 
0.99901) [15]. The molecular weight of the resultant polymer can be selected based on the choice 
of reaction conditions, in particular reaction time and temperature [15]. The reaction produces 
polymers of low polydispersity (Mw/Mn ~1.07-1.3) with a yield inversely proportional to the 
degradation time (49-75%, low MW polymer is lost in dialysis) and a weight average MW of 37.8 ± 
1.4 kDa (GC40), 16.6 ± 1.6 kDa (GC16) and 12.3 ± 1.9 kDa (GC12), respectively. 
The yield of the GC-DTPA conjugation step was 61–86% with the freeze-dried product obtained 
as an off-white/yellow cotton like product. The NMR analysis confirms the product and very low N-
acetylation levels (< 0.05 mol% at 2.0 ppm; Figure 1). Signals from the polymer and DTPA overlap 
but the benzene group at δ7.3–7.5 indicates the presence of the benzyl isothiocyanate moiety of p-
SCN-Bn-DTPA. Furthermore, a new peak for the GC anomeric proton that is normally masked 
becomes detectable at 4.4 ppm, presumably as a result of conformational changes. 
The conjugation level of GC-DTPA was measured using elemental analysis, an arsenazo III assay, 
and ITC. Based on the elemental nitrogen and sulphur the number of DTPA moles per 100 moles 
of the monomer GC was calculated as 5.15% (GC40-DTPA), 3.96% (GC16-DTPA-1), and 4.89% 
(GC12-DTPA-2), respectively (Tables  
Table 1). Gd3+ ions bind to arsenazo III to form the colorimetrically detectable complex (log K = 
15.85 [12]) only once DTPA has been saturated with Gd to form the DTPA-Gd complex (log K = 
22.46[16]). The colorimetric Gd arsenazo III complex thus allows measurement of free and GC-
DTPA chelated Gd from which the level of conjugation was determined to be 4.83% (GC40-
DTPA), 3.94% (GC16-DTPA-1), and 5.37% (GC12-DTPA-2), respectively (Tables  
Table 1). 
ITC was used to measure heat enthalpy of the GC-DTPA/Gd3+ interactions for GC16-DTPA and to 
determine the conjugation level by comparison with free DTPA and Gd (Figure 2). At the acidic 
low pH used in this experiment (pH=2), the carboxylic groups of DTPA are protonated (un-
ionised) and interactions with Gd3+occur at a slower rate. Initial Gd injections produce large peaks 
resulting from the binding of Gd3+ to DTPA. As the concentration of free DTPA reduces the heat 
reduces to the heat of dilution represented by the small peaks at the end of the curve. The 
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stoichiometry of binding is 0.4993:1 (GC16-DTPA:Gd) corresponding to a GC:DTPA molar ratio of 
3.79 ± 0.05. 
The yield for the off-white to yellow freeze-dried product was 217 mg (GC40-DTPA) and 120 mg 
(GC16-DTPA), respectively. The average ratio (ICP-AES) of Gd per mg of GC-DTPA-Gd was 0.079 
± 0.003 mg for GC40-DTPA-Gd, 0.100 ± 0.005 mg for GC16-DTPA-Gd, and 0.073 ± 0.005 mg for 
GC12-DTPA-Gd. 
9.2. Magnetic Resonance Imaging Results 
The initial biodistribution was imaged at 1 min and 29min post the intravenous administration of 
GC16-DTPA-Gd (0.1mmole Gd kg-1). The MR imaging of the trunk showed very clearly highlighted 
kidneys when compared to the pre-administration image (Figure 3). Immediately after injection 
detailed imaging shows GC40-DTPA-Gd and GC12-DTPA-Gd in the kidneys with rapid passage to 
renal pelvis and then ureter. Although the level of contrast decreased over time, the kidneys 
remained highlighted. Magnevist, when administered at the same concentration of Gd, yielded only 
low level of dynamic contrast enhancement which was somewhat more pronounced after 30 
minutes (Figure 3). Renal enhancement has been suggested as being indicative of contrast agent 
removal from the blood and elimination by the kidneys [17]. The higher molecular weight GC40-
DTPA-Gd continued to be present in the kidney for a longer period of time (≥ 30min) suggesting a 
longer plasma residence time consistent with a larger polymer MW. The data suggest these CAs 
are filtered by the kidneys and eliminated in the urine. 
The imaging properties of Magnevist, GC40-DTPA-Gd, and GC12-DTPA-Gd were compared further 
imaging the cranium (Figure 4); the data is visualised using maximum intensity projections (MIPs) in 
three directions before and after (3 min 20 sec) administration. Magnevist produces a diffuse 
enhancement because of leakage of contrast material into the brain parenchyma and surrounding 
tissues. Conversely, GC40-DTPA-Gd remains confined to the blood pool giving a much clearer 
enhancement of the brain vasculature while GC12--DTPA-Gd shows and intermediate effect. 
This blood pool selectivity dramatically changes the structures and detail that can be visualised from 
the volume data as shown by enhancement volume projections (Figure 4). These visualise regions 
with a level of enhancement greater than 20% based on the differential between pre-injection and 
post-injection contrast (t=3 min20 sec).  
The CAs show a distinct distribution with signal time profiles dependent on anatomically location. 
Regions of interest (ROI) representing brain parenchyma, blood vessels, and surrounding tissue 
were identified and signal intensities compared over time (Figure 5). All CAs show a sharp initial 
enhancement in the major blood vessel. While both Magnevist and GC12-DTPA-Gd show a brief 
peak the higher MW GC40-DTPA-Gd shows a sustained enhancement suggesting a prolonged 
plasma half-life compared to the lower MW agents. However, the signal decay at one hour suggests 
signal intensities would reach pre-contrast levels within two hours. Both polymeric CAs GC40-
DTPA-Gd and GC12-DTPA-Gd do not enhance contrast in the brain parenchyma or the 
surrounding connective tissue. Conversely the connective tissue region shows the greatest 
enhancement and longest time to peak when imaged with Magnevist, suggestive of a diffusion 
dependent accumulation. The vascular contrast enhancement using the GC40-DTPA-Gd is sufficient 
to allow anatomical identification of specific larger blood vessels using regional maximum intensity 
projections. 
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Based on the differential contrast of the high and low MW polymers these CAs were applied to the 
investigation of molecular weight dependent transport processes in solid tumours. Transport 
limitations of individual tumours were visualised by sequential imaging of low and high MW CAs 
administered to the same animal and same tumour, separated by a washout period (Figure 6). For 
all agents initial delivery of both agents to the tumour was correlated with blood supply. As would 
be expected the lower molecular weight material exhibited greater diffusion and consequently 
covered a larger area of the tumour. A volume projection highlights the overall disparity in tumour 
coverage of the two agents. The heterogeneity of distribution relates to identifiable anatomical 
structural detail but is also linked to the difference in CA molecular weight.  
 
10. Discussion (800) 
Molecular weight is one of the key factors determining biological behaviour of molecules in terms of 
biodistribution, and vascular and tissue transport. Here we explore the use of biocompatible 
polymers with defined and tailored molecular weights as the basis of a family of MRI CAs to 
explore these processes by MRI. Such CAs, having the same physical chemistry but different 
molecular weights could be adapted to serve preferentially as blood pool CAs or to study 
macromolecular transport processes. 
The potential for polymers based CAs with enhanced blood residence time has previously been 
explored. When poly-L-lysine-GTPA of increasing MW were explored as potential blood pool 
agents it has previously been shown that plasma half-life is increased and renal clearance reduced 
with increasing MW [18]. However, agents such as carboxy methyl dextran–GTPA have limited 
utility in exploring MW dependent processes because of their broad MW distribution (10-163 
kD)[19]. On the other hand, CAs with a defined molecular structure, such as dendrimers, possess 
monodisperse MWs but do not allow continuous tuning of polymer molecular weight[20]. 
MW is not only a key determinant of a CAs potential utility as a blood pool agent but can also be 
used to assess pathological transport processes. Once tumours are able to induce the growth of 
new vasculature (angiogenic switch) they may proliferate and metastasise. The developing ‘leaky’ 
vasculature allows extravasation of macromolecules that leads to an increase in interstitial pressure 
leading to diffusion limited transport into the tumour parenchyma which affects low MW drugs [21] 
but even more higher MW therapeutics such as anti-bodies, macromolecules, particulate drug 
carriers, gene delivery systems [10], and which has been linked to poor prognosis and drug 
resistance [9]. 
MRI has been applied in to understand and quantify such transport processes, in particular by 
applying DCE-MRI and associated mathematical derivation of parameters such as transfer co-
efficient, vascular volume fraction and measures of permeability and perfusion, typically applying 
models based on the unidirectional transfer of contrast material between compartments such as the 
Tofts two compartment model [22] and the three-compartment model [23]. 
The current study analyses the relationships between blood supply and contrast agent delivery 
directly and in high resolution. The data emphasises the important role of underlying anatomical 
structures and local tissue heterogeneity in determining the detailed spatiotemporal distribution of 
molecules of different molecular weight.  
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The concept of using MRI contrast agents as surrogates for drugs to investigate tumour delivery and 
transport issues itself is not new. Both low molecular weight contrast materials [24] and 
macromolecular contrast materials [25] have been used as to predict the delivery and transport of 
drugs of a similar molecular weight. In both cases the delivery of the drug confirmed by histology 
proved to be well correlated with the prediction by MRI. Furthermore studies have been 
performed in which contrast agents with different molecular weights have been serially 
administrated to the same tumour in order to optimise modelling procedures [26, 27]. The studies 
reported here would appear to be the first time that these two concepts (the use of contrast 
agents as drug surrogates and the serial administration of contrast agents with different molecular 
weights) have been brought together. 
Here we synthesise and characterise glycol chitosan (GC-DTPA-Gd3+) as a biocompatible 
macromolecular contrast agent for which the molecular weight can be tuned precisely for various 
imaging purposes. We demonstrate its utility as a blood pool agent by detailed imaging of mouse 
brain vascular architecture, show that filtration via the kidney provides early and sustained contrast 
enhancement in the kidney, and provide evidence that GC-DTPA-Gd of high and low MW can be 
used to characterise molecular weight dependent transport in murine xenograft tumours with a 
high spatial resolution. The imaging also showed that the diffusion distances for higher molecular 
weight materials were lower than for low molecular weight materials. Furthermore, there is an 
increasing appreciation of the role of spatiotemporal heterogeneity of tumour transport. Data from 
doxorubicin treated breast cancers demonstrate this heterogeneity can persist for many hours [21] 
but work in experimental tumours suggests that vascular supply can also change rapidly over time 
[28]. We believe that isotropic high-resolution three-dimensional imaging of molecular weight 
dependent transport process in tumours can help to better understand the role of heterogeneity 
for the transport of therapies in the tumour. Studies of this type using a series of well-calibrated 
CAs that differ only by MW could potentially provide a surrogate biomarker for the accessibility of 
tumours to drug treatments (based on their molecular weight) would be expected to offer good 
coverage of a specific tumour. In drug development terms this may also help in the selection of a 
suitable tumour models to test new high MW treatments. 
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12. Tables  
Table 1.Characteristics of GC-DTPA conjugates and level of conjugation, represented by number of 
GC monomers per DTPA pendant group, measured using elemental analysis, arsenazo III assay, and 
ITC. 
        Conjugation level % 
Conjugate Time (hours) MW kDa 
GC:DTPA 
(mol:mol) 
Elemental 
analysis 
Arsenazo III 
assay ITC Average 
GC40-DTPA 2 37.8 ± 1.4 01:02 5.15 4.83±0.14 n/a 4.99 
GC16-DTPA 48 16.6 ± 1.6 01:01 3.96 3.94 ± 0.19 3.79 ± 0.05% 3.9 
GC12-DTPA 48 12.3 ± 1.9 01:02 4.89 5.37±0.06 n/a 5.13 
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13. Figure legends 
 
Figure 1. Structure and annotated 1H-NMR spectra of GC-DTPA in D2O indicating the presence 
of the benzylisothiocyanate moiety of p-SCN-Bn-DTPA at δ7.3–7.5. 
 
Figure 2. Determination of the conjugation level of GC-DTPA/Gd3+ based on the measurement of 
heat enthalpy. Injection of Gd+3 (6.5 mM) into a buffered aqueous solution of GC16-DTPA (0.2 
mM based on p-SCN-Bn-DTPA, 25 oC and pH = 2) yields a titration curve showing heat flow 
against amount of injected Gd+3 (top) and of enthalpy versus molar ratio (bottom). 
 
Figure 3. Time course of trunk MR of mice imaged over 28 minutes and injected with Magnevist 
(top panel) and GC40-DTPA-Gdat 0.1mmole Gd.kg-1 (bottom panel). The polymer CAs shows an 
enhanced level of contrast over a significantly prolonged duration compared to Magnevist as well as 
early enhancement of the kidney parenchyma and renal pelvis. 
 
Figure 4. MR imaging of the head imaging after administration of (a) Magnevist, (b) GC12-DTPA-
Gd, and (c) GC40-DTPA-Gd. Left panel: Maximum intensity projections of the cranium in the 
coronal, sagittal, and transverse planes prior and 3 mins 20 sec after administration of CAs. Middle 
panel: Volume projections showing areas of greater than 20% enhancement after x minutes 
demonstrate the different levels of vascular retention of the agents. Right panel: Maximum intensity 
projections of murine brain imaged using GC40-DTPA-Gd allow visualisation of cranial vasculature 
in sufficient to allow anatomical identification of blood vessels (1-Superior sagittal sinus; 2-Lateral 
superior cerebellar artery; 3-Common carotid artery; 4-Posterior cerebral artery). 
 
Figure 5. MR images and time dependent contrast intensity profiles of the mouse cranium imaged 
using (a) Magnevist, (b) GC12-DTPA-Gd, and (c) GC40-DTPA-Gd. A number of specific 
 13 
anatomical regions of interest (ROI) were identified (square= brain parenchyma, rhombus = brain 
blood supply, triangle&cross= tissue surrounding the brain). The contrast intensity in those 
structures was then extracted from the 4D data stack and plotted over time yielding intensity-time 
curves. 
 
Figure 6.Comparison of molecular weight dependent contrast enhancement in a tumour. A431 
epidermoid carcinoma flank tumour in a mouse are imaged over a period of 20 min after 
intravenous administration of first Magnevist followed by GC40-DTPA-Gd (top panel). Changes in 
the distribution between low (Magnevist) and high MW CA (GC40-DTPA-Gd) between 0 to 10 
minutes and 10 to 20 minutes are visualised, respectively (bottom panel, left). High and low MW 
agent distribution 20 minutes after injection in the same tumour is visualised as a volume projection 
of CA distribution (bottom right panel). 
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